Gyros Protein Technologies debuts Gyrolab Generic Anti-AAV Kit to support gene therapy development

Published: 18-Jun-2024

The kit enables detection of binding antibodies against AAV vectors, allowing users to identify factors that could compromise the efficacy of AAV-associated gene therapies in the clinical stage

Gyros Protein Technologies, an immunoassay and peptide synthesiser specialist, has introduced its Gyrolab Generic Anti-Adeno Associated Virus (AAV) kit.  

The ready-to-use kit facilitates the qualitative assessment of pre-existing binding antibodies against AAV vectors, enabling screening in pre-clinical and clinical settings. 


Identifying factors that alter the efficacy of AAV gene therapies

The kit allows users to identify pre-existing immunity that could interfere with AAV-based gene therapy efficacy.

The product is designed to detect total binding anti-capsid antibodies against the most commonly used AAV serotypes, and is the first of its kind on the market for assessing pre-existing anti-AAV antibodies. 

It also removes the need for capsid labelling, reducing variability and ensuring reproducible data whilst requiring small quantities of viral capsids, preserving precious drug volumes.


Gyrolab compatibility 

The kit is optimised for use on all Gyrolab systems and expands the utility of the Gyrolab platform into the bioanalytical field of AAV-based gene therapies. 

Automation with Gyrolab systems reduces variability due to manual pipetting and speeds up workflows by reducing assay development time and generating results within 90 minutes, helping to accelerate the development of novel gene therapies.
The General Manager of the Biopharmaceutical Development Division at Gyros Protein Technologies, Mark Vossenaar, commented: “The new Gyrolab Generic Anti-AAV Kit is tailored to meet customer needs in the bioanalysis of AAV-based gene therapeutics, focusing on efficiency, resource and time-savings. This addition expands our portfolio of ready-to-use kits, providing a rapid, cost-effective solution for the detection of total binding antibodies without necessitating serotype-specific assay development or extensive optimisation.”

You may also like